Abstract: The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder—such as a mixed phenotype acute leukaemia (MPAL)—characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein.

Abstract: The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder—such as a mixed phenotype acute leukaemia (MPAL)—characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein.

Abstract: The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.

Abstract: The invention relates to a method for producing at least one closed region on a carrier surface of a carrier, wherein the method comprises the following steps: a. adding a first fluid comprising at least one cell and/or at least one particle to the carrier surface and b. adding a second fluid, wherein the second fluid is immiscible with the first fluid and at least partially covers the first fluid and c. acquiring at least one item of cell information and/or of at least one item of particle information and d. producing the closed region on the basis of the at least one acquired item of cell information and/or the at least one acquired item of particle information.

Abstract: A method presents metadata that is used for determining the color correction processes to be performed on image data representing a sequence of moving images (705). Instructions in the metadata controls how many color corrections are to be performed and when such operations occur. The image data is then subjected to the specified color correction operations that are performed at specified times and in a determined order (710). The image data is then rendered as a series of images (715) by a rendering device. Optionally, different regions of the image data may be subjected to different color correction operations.

Abstract: The present invention relates to an improved method for the identification and optionally the characterisation of interacting molecules designed to detect positive clones from the rather large numbers of false positive clones isolated by conventional two-hybrid systems. The method of the invention relies on a novel combination of selection steps used to detect clones that express interacting molecules from false positive clones. The present invention provides for high-throughput interaction screens for the reliable identification of interacting molecules, which in turn can lead to the identification of substances inhibiting said interactions. Such inhibitors can find their use in the formulation of a pharmaceutical composition. The present invention further relates to kits useful for carrying out the method of the invention.

Abstract: The present invention relates to an improved method for the identification and optionally the characterization of interacting molecules designed to detect positive clones from the rather large numbers of false positive clones isolated by two-hybrid systems. The method of the invention relies on a novel combination of selection steps used to detect clones that express interacting molecules from false positive clones. The present invention further relates to a kit useful for carrying out the method of the invention. The present invention provides for parallel, high-throughput or automated interaction screens for the reliable identification of interacting molecules.

Abstract: A plant is provided for rapid pick and place operations, enabling automated systems that return to at least one approximately fixed position to run faster than the rate of conventional systems. The plant utilises a novel combination of robotic design, linear motor technology, and control software. A system and method if provided for the rapid production of high-density arrays of biologically active substances.

Abstract: The present invention relates to an improved plant for rapid pick and place operations, enabling automated systems that return to at least one approximately fixed position to run faster than conventional systems. The present invention further relates to a system for the rapid production of high-density arrays of biologically active substances.